Insider transactions
Stephen M. Bloch, a director on the board of Liquidia Corp (NASDAQ:LQDA), sold common stock in four separate transactions on March 26 and March 27, 2026, with aggregate proceeds reported at $2.53 million. The sales were carried out at prices that spanned from $35.4214 to $37.2183 per share.
On March 26, Bloch sold 7,684 shares at a weighted average price of $37.2183, generating $286,001. The following day he executed three additional sales: 30,401 shares at a weighted average price of $35.4214 for $1,076,963; 30,176 shares at $36.3758 each for $1,097,871; and 1,973 shares at $37.1303, recorded as worth $73,29.
The insider activity occurred while Liquidia shares were trading at $35.18, a price point that represents a 133% gain over the past year. According to InvestingPro analysis cited in company reports, the stock remains below its Fair Value and analysts expect the company to become profitable within the year.
Shareholdings after the sales
After completing these transactions, Bloch's reported holdings include 2,188,935 shares held indirectly and a direct stake of 65,712 shares of Liquidia common stock.
Company results and analyst responses
Liquidia Technologies' fourth-quarter 2025 release highlighted a notable revenue contribution from its Yutrepia drug: reported sales of $90.1 million, reflecting 74% quarter-over-quarter growth. Despite the revenue strength, the company missed expectations on earnings per share.
Analysts reacted to the results and the product launch dynamics with upward revisions to price targets and maintained generally positive ratings. H.C. Wainwright raised its price target to $55 and maintained a Buy rating. BTIG increased its target to $50, citing the strong Yutrepia launch. Raymond James reiterated a Strong Buy rating with a $47 target, drawing a comparison between Yutrepia's launch and the early performance of Tyvaso DPI. BofA Securities kept a Buy rating with a $44 target and pointed to Liquidia's competitive position in the prostacyclin treatment market. The company has also issued revenue guidance of more than $1 billion for 2027.
Context and limitations
The reported insider sales and the company disclosures provide direct data points on recent ownership changes, product performance, and analyst sentiment. Where numerical entries are taken from company and reporting figures, they are presented as reported. The sale values, trade dates, share counts, reported revenues, analyst targets, and guidance are included exactly as disclosed.